Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2019.09.040 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world experience of the efficacy and safety of guselkumab 100 mg in patients with palmoplantar pustulosis in Korea: A retrospective single-center study.
JAAD Int
February 2025
Department of Dermatology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
Effectiveness and tolerability of cenobamate: A single center experience.
Epilepsy Res
December 2024
George Washington University, Department of Neurology, Washington, DC, USA. Electronic address:
Introduction: Medication-resistant epilepsy (MRE) is characterized by the failure of adequate trials of two antiseizure medications (ASMs). Numerous studies have shown that once two ASMs fail to control seizures, the likelihood of subsequent ASM regimens providing seizure control diminishes significantly. Recent clinical data on cenobamate (CNB) suggest it may offer higher rates of seizure freedom in MRE patients.
View Article and Find Full Text PDFExpectations and Outcomes From Glucagon-Like Peptide-1 Receptor Agonists As Adjunct Treatment for Type 1 Diabetes - Case Presentations.
J Diabetes Sci Technol
December 2024
Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Background: Type 1 diabetes (T1D) is characterized by the autoimmune destruction of pancreatic beta cells, leading to lifelong insulin dependence. Despite advancements in insulin therapies and glucose monitoring, maintaining optimal blood glucose control remains challenging with common issues like weight gain and glucose variability. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), approved for type 2 diabetes and obesity, are being explored off-label for T1D.
View Article and Find Full Text PDF[Six-month real-world outcomes of intravitreal clindamycin for ocular toxoplasmosis].
J Fr Ophtalmol
December 2024
Service d'ophtalmologie, hôpital Pierre-Paul-Riquet, CHU de Toulouse, place du Dr-Baylac, 31059 Toulouse, France.
Objective: To evaluate in a real-world setting an intravitreal clindamycin treatment protocol for ocular toxoplasmosis.
Methods: This was a single-center, retrospective review with a 6-month follow-up. Our protocol proposed an IVT of clindamycin as first-line treatment, and management was chosen according to the patient's status (past medical history of ocular toxoplasmosis or not).
Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration.
Clin Ophthalmol
December 2024
Department of Ophthalmology & Vision Science, University of California Davis Eye Center, Sacramento, CA, USA.
Purpose: To report our real-world experience using intravitreal faricimab, a novel anti-vascular endothelial growth factor (anti-VEGF) therapy, in eyes with neovascular age-related macular degeneration (nAMD) previously treated with other anti-VEGF therapy.
Patients And Methods: A retrospective, single-center study of previously treated nAMD eyes treated with faricimab.
Results: In 88 eyes (73 patients), mean baseline best-corrected visual acuity (BCVA) was 20/63 (range 20/20 to CF) with mean anti-VEGF injection interval of 6.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!